Question | Answer |
The ability of a test to rule out a disease | Sensitivity |
The percentage of people with cancer who will have an abnormal test | Sensitiviy |
The percentage of people without cancer whose test is negative | Specificity |
The ability of a test to rule in disease | Specificity |
Probability that people with an abnormal test actually have cancer | Positive predictive value |
Probability that a negative test will predict that a person does not have cancer | Negative predictive value |
Proteins normally found in larger amounts during fetal development | Antigens |
These are examples of which type of tumor marker; AFP, CEA, PSA, CA-125, Bence Jones Proteins | Antigens |
These are examples of which type of tumor marker; Prostatic Acid Phosphatase, Galactosyl transferase II | Enzymes |
This marker is often associated with tumors of endocrine glands | Hormones |
These are examples of which type of tumor marker; Beta-HCG, Human Calcitonin | Hormones |
Genes that are useful in fetal development but when activate in mature cells trigger tumor growth | Oncogenes |
These are examples of which type of tumor marker; BRCA 1, BRCA 2, Philadelphia chromosome | Oncogenes |
Philadelphia Chromosome is associated with which type of cancer | Chronic Myelogenous Leukemia-CML |
Cell surface proteins that affect the rate of tumor development by binding to hormones and growth factors | Tissue receptors |
These are examples of which type of tumor marker; ER assay, PR assay, EGFR | Tissue receptors |
What goes down as prevalence of disease goes down | Positive predictive value |
Increased in 80-90% of patients with hepatocellular carcinoma | Alpha-Fetoprotein (AFP) |
Patients with cirrhosis and active hepatitis should be screened with which tumor marker every 3-4 months | Alpha-Fetoprotein (AFP) |
Used primarily to detect and monitor clinical course of Multiple Myeloma. It is not found in the blood b/c it is effeciently filtered by the kidneys. Considered to be the first tumor marker. | Bence Jones Proteins |
This hormone tumor marker is normally negative except in pregnancy, and is never found in cancer free males. | Beta-HCG |
This hormone tumor marker is primarily associated with the following; Hydatidiform mole of the uterus, chriocarcinoma of the uterus, and germ cell tumors of the ovaries | Beta-HCG |
High levels of this hormone are almost always pathognomonic for germ cell neoplasm in men. | Beta-HCG |
This antigen is useful in diagnosis, evaluation of therapy, and sruveillance in patients with pancreatic and hepatobiliary cancer | CA 19-9 |
This antigen is elevated in 80-90% of women with ovarian cancer. | CA 125 |
This antigen is used in determining the extent of disease, prognosis, and response to therapy in patients with GI cancers. | Carcinoembryonic Antigen (CEA) |
Baseline for this antigen is elevated in smokers. | Carcinoembryonic Antigen (CEA) |
This antigen is used in screening for early detection of prostate cancer. | Prostate Specific Antigen (PSA) |
When combined with a digital rectal exam 90% of clinically significant cancers can be detected. | Prostate Specific Antigen (PSA) |
Not a tumor marker but a useful diagnostic tool for assessing risk of developing breast cancer in a woman in the general population | The Gail model |
This tool takes into acount these factors when assessing 5 year and lifetime risk of developing breast cancer; current age, age at menarche, previous breast biopsies, age at first live birth, family history of breast cancer. | The Gail model |
Breast cancer oncogenes | BRCA 1, BRCA 2 |
Men with this mutation carry a markedly increased risk of developing prostate cancer and or colorectal cancer, and may pass the mutation to their daughters. | BRCA 2 |
This tissue receptor indicates sensitivity to hormonal therapy. | Estrogen Receptor (ER) assay, and Progesterone Receptor (PR) Assay |
Tumors positive for this tissue receptor are more than twice as likely to respond to hormone therapy. | ER assay |
This tissue receptor is more often positive in postmenopausal breast cancer patients | PR assay |
An increased level of this antigen is associated with more aggressive breast cancers. | HER 2 (neu) |
Triple negative tumors have no hormonal target for therapy and are negative for which markers. | ER, PR, HER 2 |
This antigen is elevated in 70-80% of patients with metastatic disease, and is rarely elevated in early stage disease. | CA 15-3 |
This antigen is useful in monitoring response to therapy in metastatic breast cancer patients. | CA 27.29 |
This rare marker is associated with liquid tumors; lymphoma, leukemia, multiple myeloma. | Beta2 microglobulin |
This rare antigen is not a good screening tool b/c levels can be elevated in UTI, renal calculi, recent urinary surgery | Bladder tumor antigen (BTA) |
This rare marker is a good screening tool for patients at risk for bladder cancer | Nuclear Matrix protein 22 (NMP22) |
A sensitive marker for detection of bladder cancer across all disease stages and grades | Survivin |
This hormone is used to evaluat patients with at risk for/suspected medullary carcinoma of the thyroid. | Human Calcitonin |
This enzyme is associated with Neuroblastoma, carcinoid, and small cell lung cancer | Neuron Specific Enolase (NSA) |
This enzyme is primarily used to diagnose, stage, and monitor efficacy of treatment in prostate cancer | Prostatic Acid Phosphatase (PAP) |
This cancer has a 30% recurrence rate even decades after successful treatment | Thyroid cancer |
This protein is the primary marker for surveillance of well-differentiated thyroid cancers in postoperative patients. | Thyroglobulin |
Common tumor marker for ovarian cancer | CA 125 |
k-ras, c-myc, abl, Her2/neu are all examples of what | Oncogenes |
Genes that once mutated activates the growth pathway | Oncogenes |
Only one copy needs to be mutated to induce tumorogensis | Oncogenes |
Genes that normally inhibit growth | Tumor suppressor genes |
A mutation of these causes a loss of inhibition | Tumor suppressor genes |
Both copies need to be mutated to lose function | Tumor suppressor genes |
Classic presentation fo this type of cancer is painless jaundice | Pancreatic cancer |
Tumor marker for teratoma | Alpha-Fetoprotein (AFP) |
No meat | No treat |
Tissue | Is the issue |
In what scenario do you not need a pathological specimen to initiate treatment | Pancreatic mass |
A small needle is inserted into the mass and cells are removed for microscopic evaluation | Fine needle aspiration |
Can be done guided or unguided | Fine needle aspiration |
This type of biopsy is mainly applied to melanoma | Punch biopsy |
What type of biopsy is not indicated for suspected melanoma | Shave biopsy |
Once a tissue diagnosis positive for cancer is obtained what is the next step in treatment of the patient | Radiographic staging |
Based on the theory that lymphatic spread proceeds through a consistent anatomic network of ducts and nodes based on tumor location | Sentinel lymph node biopsy |
Looking for hot and blue nodes | Sentinel lymph node biopsy |
It is recommended that those with this disorder start haveing colonoscopies in their teens | Familial adenomatous polyposis (FAP) |
Should begin screening 10 years prior to the age of onset in the family member affected with what cancer. | Hereditary Nonpolyposis Colorectal Cancer (HNPCC) |